Tune Therapeutics
Durham and Seattle, US · 2 known investors
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
BiotechDeep TechHealthtechLongevityMedical Devices
Founders & leadership
JM
John McHutchisonCEO, Chairman of the Board
Investors · 2
In the news
- Durham’s Tune Therapeutics raises $175 million for novel trial | Raleigh News & Observernewsobserver.com · 2025
- Tune Therapeutics Completes Over $175M in Series B Financingfinsmes.com · 2025
- Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinicfiercebiotech.com · 2025
- Durham biotech firm Tune Therapeutics has raised a $175 million funding roundaxios.com · 2025
- Tune Therapeutics raises $175M Series B for epigenetic editingendpoints.news · 2025
- Tune Therapeutics - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021